Tyrosine Kinase Inhibitor-associated Fibrothorax

A 59-year-old man with chronic myelogenous leukemia, refractory to imatinib, developed recurrent bilateral chylothoraces 3 months after initiating dasatinib. Treatment was briefly held and later reinitiated with a dose reduction.

Saved in:
Bibliographic Details
Published in:American journal of respiratory and critical care medicine 2019-06, Vol.199 (11), p.1432-1432
Main Authors: Adrianza, Andres M, Jimenez, Carlos A, Aldana, Grecia L, Pozo, Leonardo, Cortes, Jorge E, Sagar, Ala Eddin S
Format: Article
Language:English
Subjects:
Chemotherapy
Dasatinib - adverse effects
Dasatinib - therapeutic use
Dyspnea
Humans
Images in Pulmonary, Critical Care, Sleep Medicine and the Sciences
Inhibitor drugs
Leukemia
Leukemia, Myeloid - drug therapy
Lungs
Male
Middle Aged
Pleural Diseases - chemically induced
Pleural Diseases - diagnostic imaging
Pleural Diseases - surgery
Protein Kinase Inhibitors - adverse effects
Protein Kinase Inhibitors - therapeutic use
Side effects
Targeted cancer therapy
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 59-year-old man with chronic myelogenous leukemia, refractory to imatinib, developed recurrent bilateral chylothoraces 3 months after initiating dasatinib. Treatment was briefly held and later reinitiated with a dose reduction.
ISSN:1073-449X
1535-4970
DOI:10.1164/rccm.201806-1155IM